Chase Investment Counsel Corp Lowers Stock Holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Chase Investment Counsel Corp lessened its stake in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 14.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 8,980 shares of the exchange traded fund’s stock after selling 1,555 shares during the quarter. Chase Investment Counsel Corp’s holdings in ProShares Ultra Nasdaq Biotechnology were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Texas Capital Bank Wealth Management Services Inc acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the first quarter valued at about $288,000.

ProShares Ultra Nasdaq Biotechnology Stock Down 5.4 %

Shares of BIB opened at $62.76 on Wednesday. The stock’s 50 day moving average is $63.82 and its two-hundred day moving average is $61.84. ProShares Ultra Nasdaq Biotechnology has a twelve month low of $40.70 and a twelve month high of $69.56.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The firm also recently declared a dividend, which was paid on Wednesday, October 2nd. Investors of record on Wednesday, September 25th were paid a $0.1528 dividend. The ex-dividend date of this dividend was Wednesday, September 25th. This is an increase from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.04.

ProShares Ultra Nasdaq Biotechnology Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.